Advanced search
Publication Cover
Journal of Blood Medicine Volume 14, 2023 - Issue
Submit an article Journal homepage
165
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura

George M Rodgers1 Division of Hematology and Hematologic Malignancies Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1234-0128View further author information
ORCID Icon,
Misa Berndt2 Sugarhouse Hematology, University of Utah, Salt Lake City, UT, USAView further author information
,
Megan Fonteno3 Clinical Pharmacy, MD Anderson Cancer Institute, Houston, TX, USAView further author information
&
Jeffrey A Gilreath2 Sugarhouse Hematology, University of Utah, Salt Lake City, UT, USA;4 Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USAORCID Iconhttps://orcid.org/0000-0002-4566-8448View further author information
ORCID Icon
Pages 209-211 | Received 19 Nov 2022, Accepted 17 Feb 2023, Published online: 02 Mar 2023

References

  • Duggan S. Caplacizumab: first global approval. Drugs. 2018;78:1639–1642. doi:10.1007/s40265-018-0989-0
  • Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–346. doi:10.1056/NEJMoa1806311
  • Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18:2496–2502. doi:10.1111/jth.15010
  • Abou-Ismail MY, Arafah Y, Fu P, et al. Outcomes of immune thrombotic thrombocytopenic purpura (iTTP) with upfront cyclophosphamide vs rituximab. Front Med. 2020;7:588526. doi:10.3389/fmed.2020.588526
  • Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368:90–92. doi:10.1056/NEJMc1213206
  • Lee NCJ, Yates S, Rambally S, et al. Bortezomib in relapsed/refractory autoimmune-mediated thrombotic thrombocytopenic purpura. A single-center case series and systematic review. American Society of Hematology Annual Meeting. Poster #1135; 2022.
  • Goshua G, Bendapudi PK. Evidence-based minireview: should caplacizumab be used routinely in unsolicited patients with immune thrombotic thrombocytopenic purpura? Hematol Am Soc Hematol Educ Program. 2022;2022:491–494. doi:10.1182/hematology.2022000412
  • Volker LA, Balduin G, Kuhne L, et al. Caplacizumab is effective in treating immune-mediated thrombotic thrombocytopenic purpura in real-world scenarios and may lower mortality: an aggregative analysis. Blood. 2021;138(Suppl 1):1019. doi:10.1182/blood-2021-153211
  • Kuhne L, Kaufeld J, Volker LA, et al. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost. 2022;20:951–960. doi:10.1111/jth.15637

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.